Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 24;14(1):35. doi: 10.3390/pharmaceutics14010035

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Treatment outcomes of MHT combined with TSL-Dox delivery by using 100 nm TSLs in a tumor with 200 nm vessel wall pore diameter. MHT is performed 9 h after TSL-Dox administration. (a) The release rate profile as a result of MHT. (b) Spatial distribution of free doxorubicin in the extracellular space of the tumor after MHT. (c) The concentration of TSL-Dox and free, bounded, and internalized Dox over time. The concentration of TSLs rapidly decreases after 9 h, because TSLs release the drug in response to temperature elevation. A dissimilar trend is shown for the concentration of bound and internalized drugs. (d) FKCs induced by release drug over time. (e) The effect of each part of the treatment on the final result.